Nguyen Huong Q, Borson Soo, Khang Peter, Langer-Gould Annette, Wang Susan E, Carrol Jarrod, Lee Janet S
Department of Research and Evaluation Kaiser Permanente Southern California Pasadena California USA.
School of Medicine Department of Psychiatry and Behavioral Sciences University of Washington Seattle Washington USA.
Alzheimers Dement (N Y). 2022 Mar 13;8(1):e12279. doi: 10.1002/trc2.12279. eCollection 2022.
In an effort to identify improvement opportunities for earlier dementia detection and care within a large, integrated health care system serving diverse Medicare Advantage (MA) beneficiaries, we examined where, when, and by whom Alzheimer's disease and related dementias (ADRD) diagnoses are recorded as well as downstream health care utilization and life care planning.
Patients 65 years and older, continuously enrolled in the Kaiser Foundation health plan for at least 2 years, and with a first ADRD diagnosis between January 1, 2015, and December 31, 2018, comprised the incident cohort. Electronic health record data were used to identify site and source of the initial diagnosis (clinic vs hospital-based, provider type), health care utilization in the year before and after diagnosis, and end-of-life care.
ADRD prevalence was 5.5%. A total of 25,278 individuals had an incident ADRD code (rate: 1.2%) over the study period-nearly half during a hospital-based encounter. Hospital-diagnosed patients had higher comorbidities, acute care use before and after diagnosis, and 1-year mortality than clinic-diagnosed individuals (36% vs 11%). Many decedents (58%-72%) received palliative care or hospice. Of the 55% diagnosed as outpatients, nearly two-thirds were diagnosed by dementia specialists; when used, standardized cognitive assessments indicated moderate stage ADRD. Despite increases in advance care planning and visits to dementia specialists in the year after diagnosis, acute care use also increased for both clinic- and hospital-diagnosed cohorts.
Similar to other MA plans, ADRD is under-diagnosed in this health system, compared to traditional Medicare, and diagnosed well beyond the early stages, when opportunities to improve overall outcomes are presumed to be better. Dementia specialists function primarily as consultants whose care does not appear to mitigate acute care use. Strategic targets for ADRD care improvement could focus on generating pragmatic evidence on the value of proactive detection and tracking, care planning, and the role of specialists in chronic care management.
为了在一个为不同的医疗保险优势(MA)受益人服务的大型综合医疗系统中确定早期痴呆症检测和护理的改进机会,我们研究了阿尔茨海默病及相关痴呆症(ADRD)诊断记录的地点、时间和人员,以及下游医疗保健利用情况和生命护理规划。
年龄在65岁及以上、连续参加凯撒基金会健康计划至少2年且在2015年1月1日至2018年12月31日期间首次被诊断为ADRD的患者组成了发病队列。电子健康记录数据用于确定初始诊断的地点和来源(诊所与医院,提供者类型)、诊断前后一年的医疗保健利用情况以及临终护理情况。
ADRD患病率为5.5%。在研究期间,共有25278人有ADRD发病代码(发病率:1.2%),近一半是在医院就诊期间确诊的。与诊所诊断的个体相比,医院诊断的患者有更高的合并症、诊断前后的急性护理使用率以及1年死亡率(36%对11%)。许多死者(58%-72%)接受了姑息治疗或临终关怀。在55%被诊断为门诊患者中,近三分之二是由痴呆症专科医生诊断的;使用标准化认知评估时,表明为中度ADRD阶段。尽管在诊断后的一年中,预先护理规划和看痴呆症专科医生的次数有所增加,但诊所和医院诊断的队列的急性护理使用率也有所增加。
与其他MA计划类似,与传统医疗保险相比,该医疗系统中ADRD的诊断不足,且在被诊断时已远远超过早期阶段,而此时改善总体预后的机会被认为更大。痴呆症专科医生主要发挥顾问作用,其护理似乎并未减少急性护理的使用。ADRD护理改进的战略目标可侧重于生成关于主动检测和跟踪、护理规划的价值以及专科医生在慢性护理管理中的作用的实用证据。